Sacubitril/valsartan in heart failure and end-stage renal insufficiency

31Citations
Citations of this article
108Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The aim of this report is to describe the feasibility and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 67-year-old man with heart failure with reduced ejection fraction due to an ischemic cardiomyopathy and renal insufficiency undergoing hemodialysis. Because of worsening heart failure with no other therapeutic options, a treatment with sacubitril/valsartan was started. Although this patient had a very low systolic blood pressure, he could tolerate a moderate dose of 49/51 mg twice daily. After initiation of sacubitril/valsartan, there was a symptomatic improvement with a clear reduction NT-proBNP, accompanied by a decrease in filling pressures. In conclusion, in this patient with severe heart failure undergoing hemodialysis, treatment with sacubitril/valsartan was feasible, safe, and improved heart failure symptoms.

Cite

CITATION STYLE

APA

Heyse, A., Manhaeghe, L., Mahieu, E., Vanfraechem, C., & Van Durme, F. (2019). Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Failure, 6(6), 1331–1333. https://doi.org/10.1002/ehf2.12544

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free